• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Thursday 04/26/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

balance sheet

  • 6:12 PM

    PALM BEACH GARDENS, FL– GDAR, (Marketwired – Feb 2, 2016) –  Golden Age Resources (OTC PINK: GDAR), a leading acquisition and development company, announced today that it has recently entered final stages of operational and financial reporting to assist in hitting key benchmarks and goals on the path to fully audited financials, greater capital, and ultimately pursuing uplisting with a clean balance sheet. In achieving these internal benchmarks and reporting requirements, management continues on a firm path towards fully integrating

    Read more
  • 4:24 PM

    Nuvilex (PublicWire.com Press Release) — NEW YORK, NY, Feb 21, 2014 (Marketwired via COMTEX) — Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with

    Read more
  • 12:09 PM

    Nuvilex http://www.Publicwire.com (PublicWire.com Press Release) — NEW YORK, NY, Feb 19, 2014 (Marketwired via COMTEX) — Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company’s pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase

    Read more
Public Wire Banner